STOCK TITAN

[Form 4] CONMED Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Todd W. Garner, Executive Vice President & CFO of CONMED Corp (CNMD), reported a single insider sale. On 08/07/2025 he sold 598 shares of CONMED common stock at $52.45 per share, and the Form 4 reports he beneficially owns 0 shares following the transaction. The Form 4 was signed via power of attorney on 08/08/2025.

Todd W. Garner, Vicepresidente esecutivo e CFO di CONMED Corp (CNMD), ha effettuato una singola vendita da insider. Il 07/08/2025 ha venduto 598 azioni ordinarie CONMED a 52,45 $ per azione; il modulo Form 4 indica che dopo l'operazione possiede beneficiariamente 0 azioni. Il Form 4 è stato firmato tramite procura il 08/08/2025.

Todd W. Garner, vicepresidente ejecutivo y director financiero de CONMED Corp (CNMD), realizó una única venta como insider. El 07/08/2025 vendió 598 acciones ordinarias de CONMED a 52,45 $ por acción; el Form 4 informa que tras la transacción posee beneficiariamente 0 acciones. El Form 4 fue firmado por poder el 08/08/2025.

CONMED Corp(CNMD)의 총괄부사장 겸 최고재무책임자(Todd W. Garner)가 내부자 단건 매각을 보고했습니다. 2025-08-07에 CONMED 보통주 598주를 주당 52.45달러에 매도했으며, Form 4에는 거래 후 그가 실질적으로 보유한 주식이 0주로 기재되어 있습니다. Form 4는 2025-08-08에 위임장을 통해 서명되었습니다.

Todd W. Garner, vice‑président exécutif et directeur financier de CONMED Corp (CNMD), a déclaré une vente d'initié unique. Le 07/08/2025, il a vendu 598 actions ordinaires CONMED à 52,45 $ par action ; le formulaire Form 4 indique qu'après la transaction il possède bénéficiairement 0 action. Le Form 4 a été signé par procuration le 08/08/2025.

Todd W. Garner, Executive Vice President & CFO von CONMED Corp (CNMD), meldete einen einzelnen Insider-Verkauf. Am 07.08.2025 verkaufte er 598 Aktien der CONMED-Stammaktien zu je 52,45 $; im Formular Form 4 wird angegeben, dass er nach der Transaktion wirtschaftlich 0 Aktien besitzt. Das Form 4 wurde am 08.08.2025 per Vollmacht unterschrieben.

Positive
  • Transaction disclosed via Form 4, satisfying Section 16 reporting requirements
  • Form signed (via power of attorney) one day after the transaction, indicating prompt filing
Negative
  • Insider sold 598 shares, and the filing reports 0 shares beneficially owned following the sale
  • No explanation provided in the filing for the reason behind the sale

Insights

TL;DR: CFO sold 598 shares at $52.45, leaving no reported beneficial holdings; transaction disclosed on filed Form 4.

The filing documents a straightforward open-market sale by the company's CFO: 598 shares were disposed of at $52.45 on 08/07/2025. The report shows the reporting person holds 0 shares after the sale, indicating no remaining beneficial ownership recorded on this form. For investors, this is a transparency action required under Section 16; the filing does not provide rationale for the sale nor indicate any derivative transactions.

TL;DR: Disclosure appears routine and signed by power of attorney; no additional governance events are reported.

The Form 4 was executed via power of attorney on 08/08/2025, which is a common administrative practice. The disclosure meets Section 16 reporting of an insider sale. There are no indications of amendments, related derivative activity, or retained indirect ownership in this filing. From a governance perspective, the form shows compliance with reporting obligations but does not provide context about insider intent or company policy impacts.

Todd W. Garner, Vicepresidente esecutivo e CFO di CONMED Corp (CNMD), ha effettuato una singola vendita da insider. Il 07/08/2025 ha venduto 598 azioni ordinarie CONMED a 52,45 $ per azione; il modulo Form 4 indica che dopo l'operazione possiede beneficiariamente 0 azioni. Il Form 4 è stato firmato tramite procura il 08/08/2025.

Todd W. Garner, vicepresidente ejecutivo y director financiero de CONMED Corp (CNMD), realizó una única venta como insider. El 07/08/2025 vendió 598 acciones ordinarias de CONMED a 52,45 $ por acción; el Form 4 informa que tras la transacción posee beneficiariamente 0 acciones. El Form 4 fue firmado por poder el 08/08/2025.

CONMED Corp(CNMD)의 총괄부사장 겸 최고재무책임자(Todd W. Garner)가 내부자 단건 매각을 보고했습니다. 2025-08-07에 CONMED 보통주 598주를 주당 52.45달러에 매도했으며, Form 4에는 거래 후 그가 실질적으로 보유한 주식이 0주로 기재되어 있습니다. Form 4는 2025-08-08에 위임장을 통해 서명되었습니다.

Todd W. Garner, vice‑président exécutif et directeur financier de CONMED Corp (CNMD), a déclaré une vente d'initié unique. Le 07/08/2025, il a vendu 598 actions ordinaires CONMED à 52,45 $ par action ; le formulaire Form 4 indique qu'après la transaction il possède bénéficiairement 0 action. Le Form 4 a été signé par procuration le 08/08/2025.

Todd W. Garner, Executive Vice President & CFO von CONMED Corp (CNMD), meldete einen einzelnen Insider-Verkauf. Am 07.08.2025 verkaufte er 598 Aktien der CONMED-Stammaktien zu je 52,45 $; im Formular Form 4 wird angegeben, dass er nach der Transaktion wirtschaftlich 0 Aktien besitzt. Das Form 4 wurde am 08.08.2025 per Vollmacht unterschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Garner Todd W

(Last) (First) (Middle)
C/O CONMED CORPORATION
11311 CONCEPT BOULEVARD

(Street)
LARGO FL 33773

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CONMED Corp [ CNMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Executive Vice President & CFO
3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/07/2025 S 598 D $52.45 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Thomas Fistek for Todd W. Garner by Power of Attorney 08/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CNMD insider Todd W. Garner report on Form 4?

The Form 4 reports that Todd W. Garner sold 598 shares of CONMED common stock on 08/07/2025 at a price of $52.45 per share and beneficially owns 0 shares after the transaction.

When was the Form 4 for CNMD filed and signed?

The transaction date is 08/07/2025 and the Form 4 was signed by power of attorney on 08/08/2025.

Does the Form 4 indicate any derivative transactions or retained indirect ownership?

No. Table II (derivative securities) contains no reported entries, and Table I shows 0 shares beneficially owned following the sale.

What position does the reporting person hold at CONMED (CNMD)?

The reporting person, Todd W. Garner, is listed as Executive Vice President & CFO of CONMED Corp.

Was this Form 4 an amendment?

No amendment date is provided; the form lists the transaction date and the signature date but does not indicate it is an amendment.
Conmed Corp

NYSE:CNMD

CNMD Rankings

CNMD Latest News

CNMD Latest SEC Filings

CNMD Stock Data

1.38B
30.78M
0.58%
114.87%
6.75%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
LARGO